Kay Hofmann

Title: Kay Hofmann: Innovator in Biopharmaceuticals

Introduction

Kay Hofmann is a distinguished inventor based in Cologne, Germany. He has made significant contributions to the field of biopharmaceuticals, particularly through his innovative patents. With a total of 4 patents to his name, Hofmann's work focuses on enhancing the efficacy of therapeutic proteins.

Latest Patents

Hofmann's latest patents include groundbreaking inventions such as "Von Willebrand Factor Variants Having Improved Factor VIII Binding Affinity." This invention relates to a polypeptide that comprises a modified von Willebrand Factor (VWF) with a higher Factor VIII binding affinity than non-modified VWF, along with its pharmaceutical applications and preparation methods. Another notable patent is for "Modified Vitamin K Dependent Polypeptides," which involves modified cDNA sequences coding for vitamin K-dependent polypeptides, including human Factor VII, human Factor VIIa, human Factor IX, and human protein C. These modifications aim to improve stability and extend plasma half-life, making them valuable for therapeutic use.

Career Highlights

Throughout his career, Hofmann has worked with reputable companies such as CSL Behring GmbH and Memorec Biotec GmbH. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in the biopharmaceutical industry.

Collaborations

Hofmann has collaborated with notable professionals in his field, including Stefan Schulte and Thomas Weimer. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Kay Hofmann's contributions to biopharmaceuticals through his patents and collaborations highlight his role as an influential inventor in the industry. His work continues to pave the way for advancements in therapeutic proteins and their applications.